Specific Multiomic Profiling in Aortic Stenosis in Bicuspid Aortic Valve Disease

Author
Date
2024-02-06Permanent link
https://hdl.handle.net/11351/11143DOI
10.3390/biomedicines12020380
ISSN
2227-9059
PMID
38397982
Abstract
Introduction and purpose: Bicuspid aortic valve (BAV) disease is associated with faster aortic valve degeneration and a high incidence of aortic stenosis (AS). In this study, we aimed to identify differences in the pathophysiology of AS between BAV and tricuspid aortic valve (TAV) patients in a multiomics study integrating metabolomics and transcriptomics as well as clinical data. Methods: Eighteen patients underwent aortic valve replacement due to severe aortic stenosis: 8 of them had a TAV, while 10 of them had a BAV. RNA sequencing (RNA-seq) and proton nuclear magnetic resonance spectroscopy (1H-NMR) were performed on these tissue samples to obtain the RNA profile and lipid and low-molecular-weight metabolites. These results combined with clinical data were posteriorly compared, and a multiomic profile specific to AS in BAV disease was obtained. Results: H-NMR results showed that BAV patients with AS had different metabolic profiles than TAV patients. RNA-seq also showed differential RNA expression between the groups. Functional analysis helped connect this RNA pattern to mitochondrial dysfunction. Integration of RNA-seq, 1H-NMR and clinical data helped create a multiomic profile that suggested that mitochondrial dysfunction and oxidative stress are key players in the pathophysiology of AS in BAV disease. Conclusions: The pathophysiology of AS in BAV disease differs from patients with a TAV and has a specific RNA and metabolic profile. This profile was associated with mitochondrial dysfunction and increased oxidative stress.
Keywords
Aortic stenosis; Mitochondrial dysfunction; Oxidative stressBibliographic citation
Martín-Núñez E, Ibarrola J, Antequera-González B, Martínez-Micaelo N, Sureda-Barbosa C, Galian-Gay L, et al. Specific Multiomic Profiling in Aortic Stenosis in Bicuspid Aortic Valve Disease. Biomedicines. 2024 Feb 6;12(2):380.
Audience
Professionals
This item appears in following collections
- HVH - Articles científics [4476]
The following license files are associated with this item:




